Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924567 | 0.93 | LMNA (0.46) | LMNABLM | |
| SCHEMBL9630991 | 0.82 | ACE2 (0.47) | LMNA | |
| SCHEMBL538230 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL20928 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL29662067 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8672325 | 0.79 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL11219674 | 0.78 | LMNA (0.70) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL6141164 | 0.76 | — | — | |
| SCHEMBL386448 | 0.76 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL11574823 | 0.76 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846970-B2 | Hydroxycitric acid derivatives and skin external preparations containing the same | SHOWA DENKO K.K. (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080234224-A1 | External Preparation For Skin | SHOWA DENKO K.K. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20070293577-A1 | Hydroxycitric Acid Derivatives And Skin External Preparations Using The Same | SHOWA DENKO K.K. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070232698-A1 | Slimming Skin External Preparation and Cosmetic Containing the Same | SHOWA DENKO K.K. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070202070-A1 | Moisture Retention Polymer Compound | SHOWA DENKO K.K. (JP) | 2007-08-30 | — | — | US | disclosed |
| EP-1811949-A1 | TOPICAL SLIMMING PREPARATION AND A COSMETIC CONTAINING A CARNITINE DERIVATIVE | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1799631-A1 | HYDROXYCITRIC ACID DERIVATIVES AND SKIN EXTERNAL PREPARATIONS CONTAINING THE SAME | Showa Denko K.K. (JP) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006033476-A1 | HYDROXYCITRIC ACID DERIVATIVES AND SKIN EXTERNAL PREPARATIONS CONTAINING THE SAME | SHOWA DENKO K.K. (JP) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005115326-A1 | TOPICAL SLIMMING PREPARATION AND A COSMETIC CONTAINING A CARNITINE DERIVATIVE | SHOWA DENKO K.K. (JP) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005094777-A1 | EXTERNAL PREPARATION FOR SKIN | SHOWA DENKO K.K. (JP) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095462-A1 | MOISTURE RETENTION POLYMER COMPOUND | SHOWA DENKO K.K. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050220744-A1 | Polysaccharide/functional compound complex | SHOWA DENKO K.K. | 2005-10-06 | — | — | US | disclosed |
| US-5741816-A | CARNITINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 1998-04-21 | — | — | US | disclosed |
| EP-0688555-A2 | Hair-growing agent | TANABE SEIYAKU CO., LTD. (JP) | 1995-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293577-A1 | Hydroxycitric Acid Derivatives And Skin External Preparations Using The Same | HAAO, CYP8B1, CUTA | LMNA 2863/4885BLM 2887/4885PTPN1 3783/4885 |
| US-20070232698-A1 | Slimming Skin External Preparation and Cosmetic Containing the Same | CPT1B, CUTA, LPL | LMNA 165/4885BLM 3532/4885PTPN1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.